[Therapy for prevention of upper gastrointestinal bleeding in patients receiving anti-thrombotic therapy]

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Context:

• Upper gastrointestinal bleeding (UGIB) is a significant risk associated with antiplatelet and anticoagulant medications.
• Previous studies indicate varying risks for UGIB with different drug classes, including aspirin, ticlopidine, clopidogrel, and newer direct oral anticoagulants (DOACs).

Purpose:

• To synthesize current evidence on the risk of upper gastrointestinal bleeding associated with various commonly used medications.
• To evaluate the efficacy of gastroprotective agents, such as proton-pump inhibitors (PPIs) and histamine H2-receptor antagonists, in mitigating medication-induced UGIB.

Summary:

• Meta-analyses show low-dose aspirin elevates UGIB risk by 1.6-8.2 times.
• Ticlopidine and clopidogrel are also associated with a high risk of UGIB.
• Evidence on GI bleeding risk for new DOACs (apixaban, dabigatran, rivaroxaban) remains inconclusive.
• Proton-pump inhibitors and histamine H2-receptor antagonists are effective in preventing aspirin-induced upper GI mucosal injury.
• PPIs significantly reduce UGIB risk in clopidogrel users, but not in warfarin users.

Impact:

• Provides critical information for clinicians managing patients on antiplatelet and anticoagulant therapies, aiding in risk assessment and prevention strategies.
• Highlights the importance of gastroprotection, particularly PPIs, in patients at high risk for medication-induced UGIB.
• Identifies gaps in current knowledge regarding the GI safety of newer anticoagulants, suggesting areas for future research.